177lu-psma-617
novartis,bayer
['ralu study', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ralu', 'bayer']
#ascogu: updates from the ralu study: how the time interval between treatment relates to outcomes in patients with #mcrpc. #gu23: abstract 73, poster session a.
Driving innovation in cancer care for patients.

By following this account you confirm that you are an HCP & accept our community guidelines: https://t.co/iYZUrNHHuk